Stockscreener 앱 받기
250.49
2.82%
6.88
전일 마감가:
$243.61
열려 있는:
$243.94
하루 거래량:
978.09K
Relative Volume:
1.14
시가총액:
$18.02B
수익:
$2.96B
순이익/손실:
$487.70M
주가수익비율:
37.52
EPS:
6.6758
순현금흐름:
$344.00M
1주 성능:
+0.62%
1개월 성능:
-7.85%
6개월 성능:
+1.73%
1년 성능:
+25.80%
1일 변동 폭
$242.14
$250.53
1주일 범위
$227.49
$259.90
52주 변동 폭
$187.43
$322.34
West Pharmaceutical Services Inc Stock (WST) Company Profile
명칭
West Pharmaceutical Services Inc
전화
(610) 594-2900
주소
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
250.49 | 17.53B | 2.96B | 487.70M | 344.00M | 6.6758 |
|
ISRG
Intuitive Surgical Inc
|
485.84 | 169.97B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
175.89 | 50.58B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
79.20 | 38.58B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.55 | 37.11B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
252.55 | 35.80B | 5.40B | 1.49B | 1.78B | 10.12 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-09-15 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-24 | 개시 | Barclays | Equal Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-01-08 | 개시 | Citigroup | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2024-12-12 | 업그레이드 | UBS | Neutral → Buy |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-04-11 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-11-30 | 개시 | UBS | Neutral |
| 2022-10-28 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | 개시 | Stephens | Equal-Weight |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-04-24 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-04-23 | 개시 | William Blair | Outperform |
| 2018-04-25 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | 개시 | Stephens | Equal-Weight |
| 2017-09-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-10-28 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | 개시 | Wells Fargo | Outperform |
| 2010-05-14 | 재확인 | UBS | Neutral |
| 2010-02-23 | 개시 | Jefferies & Co | Buy |
| 2008-12-19 | 개시 | UBS | Neutral |
모두보기
West Pharmaceutical Services Inc 주식(WST)의 최신 뉴스
West Pharmaceutical Services (WST): Barclays Lowers Price Target - GuruFocus
West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2025 Earnings Call Transcript - Insider Monkey
West Pharmaceutical Services Q4 Earnings Call Highlights - Yahoo Finance
West Pharmaceutical targets 5%–7% organic revenue growth for 2026 as HVP demand accelerates - MSN
West Pharma forecasts 2026 profit above estimates on strong demand for drug components - 104.1 WIKY
Earnings call transcript: West Pharmaceutical Services Q4 2025 earnings beat expectations - Investing.com Canada
West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook - Yahoo Finance
West Pharmaceutical Q4 2025 slides: Revenue up 7.5%, EPS exceeds expectations - Investing.com Nigeria
West Pharmaceutical Services (NYSE:WST) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
West Pharmaceutical Services's (NYSE:WST) Q4 CY2025: Beats On Revenue, Stock Soars - Finviz
WST's Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up - Finviz
Iron Mountain Projects Double-Digit Growth in 2026 - Investing.com
West Pharmaceutical Q4 2025 slides: Revenue up 7.5%, EPS exceeds expectations By Investing.com - Investing.com India
West Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
West Pharmaceutical Services (NYSE:WST) Issues FY 2026 Earnings Guidance - MarketBeat
In the latest conference call, West Pharmaceutical Services Inc executives noted that although demand for GLP-1 drugs is showing strong growth momentum in 2025, the growth pace is expected to slow down in 2026. - Bitget
West Pharmaceutical (WST) Exceeds Market Expectations with Stron - GuruFocus
West Pharmaceutical Services, Inc. $WST Shares Sold by ING Groep NV - MarketBeat
West Pharma (WST) Q4 2025 Earnings Call Transcript - The Globe and Mail
West Pharmaceutical Services Posts Solid Q4 and 2025 Results - TipRanks
West Pharmaceutical (WST) Exceeds Revenue Expectations in Q4 - GuruFocus
West Pharmaceutical Services (WST) Projects FY26 Revenue Range - GuruFocus
Q4 Earnings Update: IRM, USFD, and WST Post Solid Q4 Results - Tokenist
Form 8-K WEST PHARMACEUTICAL SERV For: Feb 12 - StreetInsider
West Pharmaceutical Q4 EPS Beats Estimates; Guides 2026 Sales Growth of 5% to 7% - AlphaStreet News
West Pharmaceutical Services (WST) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
West Pharmaceutical: Q4 Earnings Snapshot - kare11.com
West Pharmaceutical Servs Q4 Earnings Summary & Key Takeaways - Benzinga
WEST PHARMACEUTICAL SVSC ($WST) Releases Q4 2025 Earnings - Quiver Quantitative
West Pharma shares climb over 5% on strong fourth-quarter results - Investing.com UK
West Pharma shares climb over 5% on strong fourth-quarter results By Investing.com - Investing.com Nigeria
West Pharmaceutical: Q4 Financial Results Overview - Bitget
(WST) West Pharmaceutical Services, Inc. Expects Q1 Adjusted EPS Range $1.65$1.70 - marketscreener.com
West Pharmaceutical Services earnings beat by $0.20, revenue topped estimates - Investing.com Canada
West Pharmaceutical Services’s (NYSE:WST) Q4 CY2025: Beats On Revenue, Stock Soars - Yahoo Finance
(WST) West Pharmaceutical Expects 2026 Net Sales Range $3.22B to $3.28B, vs. FactSet Est of $3.24B - marketscreener.com
West Reports Fourth-Quarter and Full-Year 2025 Results – Company Announcement - Financial Times
Is West Pharmaceutical Services (NYSE:WST) a Pillar In S&P 500 Futures Performance - Kalkine Media
West Pharmaceutical faces earnings test as estimates drift lower By Investing.com - Investing.com Canada
Evaluating West Pharmaceutical Services (WST) Valuation As Earnings And GLP 1 Growth Stay In Focus - Sahm
West Pharmaceutical Services, Inc. (NYSE:WST) Receives Average Rating of "Buy" from Brokerages - MarketBeat
West Pharmaceutical Services Earnings Preview: Analysts Project $793.4M RevenueNews and Statistics - IndexBox
West Pharmaceutical Services Earnings: What To Look For From WST - Finviz
West Pharmaceutical Services Inc (WST)'s Winning Formula: Financ - GuruFocus
Countdown to West Pharmaceutical (WST) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Jefferies Adjusts Price Target on West Pharmaceutical Services to $295 From $365, Maintains Buy Rating - marketscreener.com
Rockland Trust Co. Buys 5,087 Shares of West Pharmaceutical Services, Inc. $WST - MarketBeat
WST Q4 Earnings Preview: Can HVP Momentum Continue to Drive Margins? - TradingView
Envestnet Asset Management Inc. Cuts Position in West Pharmaceutical Services, Inc. $WST - MarketBeat
Why The Narrative Around West Pharmaceutical Services (WST) Is Shifting After New Valuation Updates - Yahoo Finance
West Pharmaceutical Services, Inc. (WST): A Bull Case Theory - Insider Monkey
West Pharmaceutical Services Inc (WST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
0.53%
자본화:
|
볼륨(24시간):